COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

被引：0
|
作者：
Yosuke, Tanaka [1 ]
Mitsunori, Hino [1 ]
Naomi, Onda [1 ]
Hiroyuki, Takoi [1 ]
Seiji, Kosaihira [1 ]
Norihisa, Motohashi [1 ]
Akihiko, Gemma [1 ]
机构：
[1] Chiba Hokusoh Hosp, Resp Dis Ctr, Nippon Med Sch, Chiba, Japan
来源：
RESPIROLOGY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P-F-073
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
    Petite, Sarah E.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 696 - 705
  • [2] Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    PHARMACOTHERAPY, 2017, 37 (04): : 447 - 455
  • [3] Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
    Yuasa, Mizuki
    Tanaka, Yosuke
    Tanaka, Tohru
    Kashiwada, Takeru
    Taniuchi, Namiko
    Saito, Yoshinobu
    Seike, Masahiro
    Hino, Mitsunori
    Gemma, Akihiko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [4] Long-acting muscarinic antagonist and long-acting beta 2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
    Makino, Takashi
    Otsuka, Hajime
    Hata, Yoshinobu
    Koezuka, Satoshi
    Azuma, Yoko
    Isobe, Kazutoshi
    Sugino, Keishi
    Ebihara, Sitorlt
    Homma, Sakae
    Iyoda, Akira
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 647 - 652
  • [5] Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for COPD: A systematic review and meta-analysis
    Horita, Nobuyuki
    Miyazawa, Naoki
    Tomaru, Koji
    Inoue, Miyo
    Kaneko, Takeshi
    RESPIROLOGY, 2015, 20 (08) : 1153 - 1159
  • [6] Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment
    Yang, Sheau-Ning
    Ko, Hsin-Kuo
    Hsiao, Yi-Han
    Su, Kang-Cheng
    Chang, Yuh-Lih
    Huang, Hsin-Yi
    Perng, Diahn-Warng
    Chung, Mei-Ing
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (06) : 488 - 494
  • [7] Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease
    Yongqian Xu
    Yu Pang
    Pharmaceutical Chemistry Journal, 2023, 57 : 365 - 372
  • [8] CLINICAL EFFICACY OF LONG-ACTING β2 AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONIST FOR MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Xu, Yongqian
    Pang, Yu
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2023, 57 (3) : 365 - 372
  • [9] Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
    Eung Gu Lee
    Youlim Kim
    Yong Il Hwang
    Kwang Ha Yoo
    So Eun Lee
    Kyung Yoon Jung
    Doik Lee
    Yong Bum Park
    Chin Kook Rhee
    Scientific Reports, 13
  • [10] Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
    Lee, Eung Gu
    Kim, Youlim
    Hwang, Yong Il
    Yoo, Kwang Ha
    Lee, So Eun
    Jung, Kyung Yoon
    Lee, Doik
    Park, Yong Bum
    Rhee, Chin Kook
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345